ArticleCell death & disease2014

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

H-C Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.